Sandoz's Somatropin Becomes First Biosimilar Approved In Japan
This article was originally published in The Pink Sheet Daily
Executive Summary
Japan's Ministry of Health, Labor and Welfare approved the recombinant human growth hormone injection less than a year after releasing draft guidelines and three months after Sandoz/Novartis submitted the application.
You may also be interested in...
Korea FDA Gears Up To Release Biosimilar Guidelines Modeled After EU Rules
SEOUL - South Korea's FDA is getting ready to release - possibly by the end of May - an initial version of guidelines for approval and registration of biosimilars modeled after European Union rules. The guidelines will wrap up KFDA's year-long drive to set up a regulatory framework for the new breed of follow-on biologics
Korean LG Life Sciences Plans BLA Submission For Biosimilar Somatropin To U.S. FDA
SEOUL - South Korea's LG Life Sciences completed its Phase III clinical trial of its slow-release recombinant human growth hormone somatropin weekly injection for treating adults with growth hormone deficiency, and is getting its biologics license application ready for U.S. FDA for the new formulation
Japan Chemical Research, Kissei Submit First Biosimilar Application In Japan
TOKYO - Japan Chemical Research Pharmaceutical of Kobe in Western Japan and Kissei Pharmaceutical of Matsumoto City in central Japan have applied to the Ministry of Health, Labor and Welfare for marketing what is expected to be Japan's first biosimilar therapeutic, spokespersons for the two companies told PharmAsia News Nov. 26